The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis
Open accessAbstract
The American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma and Immunology Executive Committees formed the Omalizumab Joint Task Force with the purpose of reviewing the Genentech Xolair (omalizumab) clinical trials and postmarketing surveillance data on anaphylaxis and anaphylactoid reactions. Using the definition of anaphylaxis proposed at a 2005 multidisciplinary symposia, the Omalizumab Joint Task Force concluded that 35 patients had 41 episodes of anaphylaxis associated with Xolair (omalizumab) administration between June 1, 2003, and December 31, 2005. With 39,510 patients receiving Xolair (omalizumab) during the same period of time, this would correspond to an anaphylaxis-reporting rate of 0.09% of patients. Of those 36 events for which the time of reaction was known, 22 (61%) reactions occurred in the first 2 hours after one of the first 3 doses. Five (14%) of the events after the fourth or later doses occurred within 30 minutes. Considering the timing of these 36 events, an observation period of 2 hours for the first 3 injections and 30 minutes for subsequent injections would have captured 75% of the anaphylactic reactions. The OJTF report provides recommendations for physicians who prescribe Xolair (omalizumab) on (1) the suggested wait periods after administration and (2) patient education regarding anaphylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, omalizumab has been associated with anaphylactic reactions in 0.09% to 0.2% of patients, with current recommendations to monitor patients for 30 minutes following administration.1742,1743”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1742]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The estimated rate of systemic reaction from a pollen-food allergy is 10% and the estimated rate of anaphylaxis is 1.7% to 10%.1742,1919,1920”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1742]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N., Bock, S. A., Branum, A., Brown, S., Camargo, C. A., Cydulka, R., Galli, S., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,170
Self-citationSymposium on the definition and management of anaphylaxis: summary report.
Sampson, H., Muñoz-Furlong, A., Bock, S., Schmitt, C., Bass, R., Chowdhury, B., Decker, W., Furlong, T., Galli, S., Golden, D., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 640
Self-citationThe Incidence and Management of Infusion Reactions To Infliximab: A Large Center Experience
Cheifetz, A. S., Smedley, M. V., Martin, S., Reiter, M., Leone, G., Mayer, L., & Plevy, S. E. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07457.x · Cited by 491
The diagnosis and management of anaphylaxis
Lieberman, P., Kemp, S., Oppenheimer, J., Lang, D., Bernstein, I., Nicklas, R., Anderson, J. A., Bernstein, D., Bernstein, J., Fink, J., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 296
Anaphylaxis, killer allergy: Long-term management in the community
Simons, F. E. R. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.002 · Cited by 224
Self-citationMonoclonal antibodies, immunogenicity, and associated infusion reactions.
Cheifetz, A. S., & Mayer, L. (2005) · PubMed · Cited by 152
Price, K. S., & Hamilton, R. G. (2007) · Allergy and Asthma Proceedings · doi:10.2500/aap.2007.28.3003 · Cited by 143
Desensitization for drug allergy
Castells, M. (2006) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3280108716 · Cited by 122
Steele, R. H., Limaye, S., Cleland, B., Chow, J. S. F., & SURANYI, M. G. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00389.x · Cited by 93
Baudouin, V., Crusiaux, A., Haddad, É., Schandené, L., Goldman, M., Loirat, C., & Abramowicz, D. (2003) · Transplantation · doi:10.1097/01.tp.0000073809.65502.8f · Cited by 83
Cited by
Sorted by citations
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
IgE, mast cells, basophils, and eosinophils
Stone, K. D., Prussin, C., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.017 · Cited by 1,702
Allergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256
Self-citationThe safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,185
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 982
Metadata
- Authors
- Cox, L., Platts-Mills, T. A. E., Finegold, I., Schwartz, L. B., Simons, F. E. R., & Wallace, D. V.
- Affiliations
- Nova Southeastern University (US)
- St. Luke's-Roosevelt Hospital Center (US)
- Virginia Commonwealth University (US)
- University of Manitoba (CA)
- Corresponding author
- Cox, Linda
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 120
- Issue
- 6
- Pages
- 1373-1377
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2010946738
- Cited by
- 295
- References
- 14
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 6 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 26 · 2019: 21 · 2018: 10 · 2017: 15 · 2016: 16 · 2015: 14 · 2014: 18 · 2013: 10 · 2012: 12
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Sanofi
- Teva Pharmaceutical Industries
- National Institutes of Health
- Genentech
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- omalizumab, anaphylaxis, anaphylactoid reactions, drug hypersensitivity, post-marketing surveillance, clinical trial safety, patient education, prescribing recommendations
- MeSH terms
- Academies and Institutes, Omalizumab, Allergy and Immunology, Anaphylaxis, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Asthma, Humans, United States, Anti-Allergic Agents, Anti-Asthmatic Agents, Advisory Committees, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
